Robert Vanhaeften

Mar 22, 2024 | thelancet.com | Nicholas M Fountain-Jones |Robert Vanhaeften |Jan Williamson |Janelle Maskell

SummaryContinued SARS-CoV-2 infection among immunocompromised individuals is likely to play a role in generating genomic diversity and the emergence of novel variants. Antiviral treatments such as molnupiravir are used to mitigate severe COVID-19 outcomes, but the extended effects of these drugs on viral evolution in patients with chronic infections remain uncertain. This study investigates how molnupiravir affects SARS-CoV-2 evolution in immunocompromised patients with prolonged infections.